During the past 12 months, Sanofi's average Dividends Per Share Growth Rate was 5.60% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 4.20% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 3.10% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 2.30% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Sanofi was 37.90% per year. The lowest was -15.60% per year. And the median was 4.55% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Competitive Comparison of Sanofi's Forward Dividend Yield %
For the Drug Manufacturers - General subindustry, Sanofi's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Sanofi's Forward Dividend Yield % falls into.
Sanofi Forward Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Sanofi Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
USD 2.037356
2024-05-09
2024-05-10
2024-06-06
Cash Dividend
annually
USD:USD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Sanofi's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
2.037356
/
52.90
=
3.85 %
Current Share Price is $52.90. Sanofi's Dividends per Share for the forward twelve months is calculated as $2.037356 * 1 = $2.037356.
Sanofi's Trailing Annual Dividend Yield (%) for Today is calculated as
Trailing Annual Dividend Yield
=
Most Recent Full Year Dividend
/
Current Share Price
=
2.037356
/
52.90
=
3.85 %
Current Share Price is $52.90. Sanofi's Dividends per Share for the trailing twelve months (TTM) ended in Today is $2.037356.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Thank you for viewing the detailed overview of Sanofi's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNY has been successfully added to your